Olaparib and durvalumab in patients with DNA damage repair alterations and biochemically recurrent prostate cancer Journal Article

   

Authors:	Autio, K. A.; McHugh, D. J.; Rathkopf, D. E.; Xiao, H.; Merugu, S.; Wong, P.; Jan, M.; Dorff, T. B.; Heath, E. I.; Scher, H. I.
Article Title:	Olaparib and durvalumab in patients with DNA damage repair alterations and biochemically recurrent prostate cancer
Keywords:	prostate cancer; immunotherapy; biochemical recurrence; men; androgen-deprivation therapy; parp inhibitor; adt
Journal Title:	Journal of Immunotherapy and Precision Oncology
Volume:	8
Issue:	2
ISSN:	2666-2345
Publisher:	Innovative Healthcare Institute
Date Published:	2025-05-01
Start Page:	172
End Page:	176
Language:	English
ACCESSION:	WOS:001477388500007
DOI:	10.36401/jipo-24-36
PROVIDER:	wos
PMCID:	PMC12010483
PUBMED:	40270785
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF. Corresponding MSK author is Karen A. Autio -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/225810